Bruker (NASDAQ:BRKR) Lowered to Hold Rating by Zacks Research

Zacks Research downgraded shares of Bruker (NASDAQ:BRKR) from a strong-buy rating to a hold rating in a research note released on Wednesday,Zacks reports.

Several other equities analysts have also recently weighed in on the company. TD Cowen restated a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. Weiss Ratings restated a “sell (d+)” rating on shares of Bruker in a report on Monday. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Wolfe Research started coverage on Bruker in a report on Monday, June 1st. They issued a “peer perform” rating on the stock. Finally, Guggenheim raised their price target on Bruker from $50.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $56.64.

Bruker Stock Up 0.7%

NASDAQ:BRKR opened at $59.41 on Wednesday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85. The firm has a market cap of $9.05 billion, a P/E ratio of -84.87, a P/E/G ratio of 1.81 and a beta of 1.26. Bruker has a fifty-two week low of $28.95 and a fifty-two week high of $65.30. The firm has a 50-day simple moving average of $58.81 and a two-hundred day simple moving average of $48.57.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. The company had revenue of $838.50 million during the quarter, compared to analysts’ expectations of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.Bruker’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.32 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts predict that Bruker will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, September 21st. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker’s dividend payout ratio (DPR) is -28.57%.

Institutional Investors Weigh In On Bruker

Hedge funds have recently modified their holdings of the business. Royal Bank of Canada increased its holdings in Bruker by 8.3% in the 1st quarter. Royal Bank of Canada now owns 123,336 shares of the medical research company’s stock worth $5,148,000 after buying an additional 9,501 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in Bruker in the first quarter valued at approximately $262,000. Goldman Sachs Group Inc. increased its position in shares of Bruker by 107.3% in the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock valued at $61,162,000 after buying an additional 758,301 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Bruker by 2.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 366,204 shares of the medical research company’s stock worth $15,285,000 after acquiring an additional 9,235 shares in the last quarter. Finally, Focus Partners Wealth raised its position in Bruker by 115.0% during the first quarter. Focus Partners Wealth now owns 11,232 shares of the medical research company’s stock worth $469,000 after acquiring an additional 6,008 shares during the period. Hedge funds and other institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.